Differential chemosensitivity in oncogene-transformed cells

Journal of Experimental Therapeutics and Oncology

Volumn 1, Issue 3, 1996, Pages 162-170

  Hiwasa, T ^a   Tokita, H ^a   Ike, Y ^b  

^a CHIBA CANCER CENTER   (Japan)

^b MITSUI CHEMICALS INC   (Japan)

Author keywords

5 fluorouracil; Aclarubicin; Cancer chemotherapy; Mitomycin C; ras oncogene

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; COLORING AGENT; INTERCALATING AGENT; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; CELL DIVISION; CELL LINE; CELL TRANSFORMATION; DRUG EFFECT; DRUG RESISTANCE; GENETICS; MOUSE; MOUSE STRAIN; ONCOGENE; PHYSIOLOGY; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL DIVISION; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; COLORING AGENTS; DRUG RESISTANCE, NEOPLASM; INTERCALATING AGENTS; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; ONCOGENES; RATS; TETRAZOLIUM SALTS; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 0030132069     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Field JK, Spandidos DA. The role of ras and myc oncogenes in human solid tumors and their relevance in diagnosis and prognosis (review). Anti-cancer Res 10: 1-22, 1990.
2. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1990.
3. Kiaris H, Spandidos DA. Mutations of ras genes in human tumours (review). Int J Oncol 7: 413-421, 1995.
4. Hiwasa T. Ras inhibitors (review). Oncol Rep 3: 7-14, 1996.
5. Uehara Y, Hori M, Takeuchi T, Umezawa H. Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': Identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn J Cancer Res 76: 672-675, 1985.
6. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinase. J Biol Chem 262: 5592-5595, 1987.
7. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assay. J Immunol Methods 65: 55-63, 1983.
8. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357, 1986.
9. Mosmann TR, Fong TAT. Specific assays for cytokine production by T cells, J Immunol Methods 116: 151-158, 1989.
10. Hiwasa T, Soeda C, Takanohashi S, Kobayashi H, Suzuki A, Ueyama T, Ike Y. Screening of peptides which suppress the proliferation of transformed cells. Int J Oncol 8: 125-129, 1996.
11. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
12. Oki T, Matsuzawa Y, Yoshimito H, et al. New anti-tumor antibiotics, aclacinomycin A and B. J Antibiot 28: 830-834, 1975.
13. Cersosimo RJ, Hong WK. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analog. J Clin Oncol 4: 425-439, 1986.
14. Umezawa H, Takahashi Y, Kinoshita M, et al. Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot 32: 1082-1084, 1979.
15. Sladek N. Metabolism of oxazaphosphorines. Pharmacol Ther 37: 301-355, 1988.
16. Arakawa M, Shimizu F, Okada N. Effect of 1-(4-amino-2-methylpyrimidine-5-yl)-methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride on leukemia L-1210. Jpn J Cancer Res 65: 21-25, 1974.
17. Wakaki S, Marumo H, Tomioka K, et al. Isolation of new fractions of antitumor mitomycins. Antibiot Chemother 8: 228-240, 1958.
18. Takita T, Muraoka Y, Nakatani T, et al. Chemistry of bleomycin. XIX. Revised structures of bleomycin and phleomycin. J Antibiot 31: 801-804, 1978.
19. Shenkenberg TD, Von Hoff DD. Mitoxantrone: A new anti-cancer drug with significant clinical activity. Ann Intern Med 105: 67-81, 1986.
20. Davis HL. Chemotherapy of large bowel cancer. Cancer 50: 2638-2646, 1982.
21. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 330: 1136-1142, 1994.
22. Warne PH, Viciana PR, Downward J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 364: 352-355, 1993.
23. Ozaki S, Ike Y, Mizuno H, Ishikawa K, Mori H. 5-Fluorouracil derivatives. I. The synthesis of 1-carbamoyl-5-fluorouracils. Bull Chem Soc Jpn 50: 2406-2412, 1977.
24. Srimatkandada S, Medina WD, Cashmore AR, et al. Amplification and organization of dihydrofolate reductase genes in a human leukemic cell line, K-562, resistant to methotrexate. Biochemistry 22: 5774-5781, 1983.
25. Sklar MD. Increased resistance to cis-diamminedichloroplatinum(II) in HIH 3T3 cells transformed by ras oncogenes, Cancer Res 48: 793-797, 1988.
26. Wani MA, Xu X, Stambrook PJ. Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells. Cancer Res 54: 2504-2508, 1994.
27. Nooter K, Boersma AWM, Oostrum RG, Burger H, Jochemsen AG, Stoter G. Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. Br J Cancer 71: 556-561, 1995.
28. Lowy DR, Willumsen BM. Function and regulation of ras. Annu Rev Biochem 62: 851-891, 1993.
29. Yoshida M, Murai H, Miura S. Effects of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a new anti-tumor agent for oral use, against recurrent cases of breast cancer. Jpn J Cancer Chemother 7: 262-266, 1980.
30. Okabayashi K, Koyama Y, Maruyama K, Okazaki N, Sakano T, Ise T. Clinical trials of a new anticancer drug, 1-hexylcarbamoyl-5-fluorouracil. Jpn J Clin Oncol 9: 35-40, 1979.
31. Dietal M. What's new in cytostatic drug resistance and pathology? Pathol Res Pract 187: 892-905, 1991.